ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
1.820
-0.090 (-4.71%)
At close: Nov 4, 2024, 4:00 PM
1.860
+0.040 (2.20%)
Pre-market: Nov 5, 2024, 5:12 AM EST
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,123,394
Market Cap
1.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 84 |
| Applied DNA Sciences | 55 |
| Sintx Technologies | 43 |
| Bluejay Diagnostics | 10 |
| Entero Therapeutics | 9 |
| Allarity Therapeutics | 6 |
| IMAC Holdings | 4 |
| Salarius Pharmaceuticals | 2 |
ZVSA News
- 6 days ago - ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - GlobeNewsWire
- 13 days ago - ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewsWire
- 18 days ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - GlobeNewsWire
- 20 days ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors - GlobeNewsWire
- 4 weeks ago - ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - GlobeNewsWire
- 3 months ago - ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation - GlobeNewsWire
- 3 months ago - ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults - GlobeNewsWire